Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2014. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs). Specifically, it details the vesting and lapsing of conditional share awards under the 2009 Performance Share Plan and the 2009 Deferred Annual Bonus Plan for awards granted in 2010 and 2011.
Key Financial Metrics and Compensation Outcomes
The filing does not report consolidated revenue, profit, cash flow, or debt metrics. Instead, it provides specific data on executive compensation outcomes based on performance metrics for the period ending December 31, 2013:
- 2010 Performance Share Plan (4-year period): The Total Shareholder Return (TSR) condition resulted in a full lapse of the 30% of awards subject to this metric. GSK's TSR ranked 9th out of 10 comparator companies.
- 2011 Performance Share Plan (3-year period):
- Adjusted Free Cash Flow: 52% of this element vested (13% of total award).
- TSR: Full lapse of this element (25% of total award) as GSK ranked 7th out of 10.
- R&D New Products Sales: 65.4% of this element vested (16.3% of total award).
- Business Diversification: 41.9% of this element vested (10.5% of total award).
- Total Vesting: 39.8% of the total 2011 award vested.
- Deferred Annual Bonus Plan: Matching shares vested at 39.8% consistent with the 2011 PSP performance.
- Share Prices at Vesting (Feb 13, 2014): Ordinary Share: £16.53; ADS: US$55.06.
Material Changes and Performance Drivers
The primary material change reported is the significant reduction in executive equity compensation due to underperformance against Total Shareholder Return (TSR) benchmarks in both the 2010 and 2011 plan cycles. While GSK met thresholds for Adjusted Free Cash Flow, R&D New Product Sales, and Business Diversification, the TSR rankings (9th and 7th out of 10 peers) triggered full lapses for the TSR-weighted portions of the awards.
Outlook, Risks, and Unusual Items
The filing contains no forward-looking guidance, management commentary on future strategy, or discussion of general business risks. The document is strictly a regulatory disclosure of past compensation events. No unusual items or contingencies affecting the company's financial position are described in this text.
Key Facts for Investor Verification
- Verify the specific TSR comparator group used by GSK to understand the context of the "below median" ranking.
- Confirm the total number of shares lapsed versus vested for Executive Directors (e.g., Sir Andrew Witty, Dr. M. Slaoui) to assess the impact on executive retention and alignment.
- Review the full 2013 annual report to correlate the partial vesting of R&D and Diversification metrics with the company's broader financial performance.
- Note that the filing does not provide data on the company's overall liquidity, debt levels, or revenue trends.